对于糖尿病血液透析患者，他汀类药物有效吗？4D 研究的长期随访结果支持最初的结论。

Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study.

机构信息

Centre for Nephrology, University College London, London, UK.

Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.

出版信息

Kidney Int. 2016 Jun;89(6):1189-91. doi: 10.1016/j.kint.2016.02.045.

DOI:10.1016/j.kint.2016.02.045

PMID:27181775

Abstract

The clinical benefits of statins in dialysis patients are unproven. New follow-up data from the 4D Study indicate no clear reduction in cardiovascular events among patients with type-2 diabetes. Assessing outcomes 7.4 years beyond the randomization period (20 mg atorvastatin versus placebo), no differences in a composite cardiovascular outcome were observed and no safety concerns emerged. Current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines do not need updating based on these new data.

摘要

他汀类药物在透析患者中的临床获益尚未得到证实。来自 4D 研究的新随访数据表明，2 型糖尿病患者的心血管事件并未明显减少。在随机分组后 7.4 年评估结果（阿托伐他汀 20mg 与安慰剂），复合心血管结局无差异，也未出现安全性问题。根据这些新数据，目前的肾脏病：改善全球预后（KDIGO）指南无需更新。